Plain-English translation of NCT07085728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether , combined with two other standard myeloma drugs (bortezomib and ), works better than the current standard treatment for newly diagnosed multiple myeloma patients whose cancer has damaged their kidneys. The trial will compare how well the medication helps restore kidney function over four treatment cycles, and whether it is safe and well-tolerated.
Many multiple myeloma patients develop kidney damage from their disease, which can be serious and life-threatening. Doctors want to know if this newer medication, when added to standard treatment, can help heal damaged kidneys better than the current approach.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the standard treatment or the new medication combination, given alongside bortezomib and , over four treatment cycles. You will have regular clinic visits for blood tests, imaging, and kidney function monitoring to see how your kidneys respond. The study team will also track how well your myeloma responds and watch for any side effects throughout your treatment.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States